Apontis Pharma AG
XETRA:APPH
Income Statement
Earnings Waterfall
Apontis Pharma AG
Revenue
|
63.8m
EUR
|
Cost of Revenue
|
-25.4m
EUR
|
Gross Profit
|
38.5m
EUR
|
Operating Expenses
|
-47.1m
EUR
|
Operating Income
|
-8.7m
EUR
|
Other Expenses
|
2.1m
EUR
|
Net Income
|
-6.6m
EUR
|
Income Statement
Apontis Pharma AG
Dec-2021 | Jun-2022 | Dec-2022 | Mar-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||
Revenue |
51
N/A
|
55
+8%
|
56
+1%
|
66
+18%
|
37
-44%
|
28
-25%
|
51
+81%
|
64
+26%
|
|
Gross Profit | |||||||||
Cost of Revenue |
(17)
|
(20)
|
(21)
|
(24)
|
(14)
|
(10)
|
(19)
|
(25)
|
|
Gross Profit |
34
N/A
|
36
+5%
|
35
-1%
|
41
+19%
|
23
-44%
|
18
-23%
|
32
+77%
|
38
+21%
|
|
Operating Income | |||||||||
Operating Expenses |
(29)
|
(31)
|
(32)
|
(40)
|
(33)
|
(28)
|
(41)
|
(47)
|
|
Selling, General & Administrative |
(20)
|
(17)
|
(20)
|
(23)
|
(21)
|
(19)
|
(26)
|
(29)
|
|
Depreciation & Amortization |
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(3)
|
(3)
|
|
Other Operating Expenses |
(8)
|
(12)
|
(10)
|
(15)
|
(10)
|
(7)
|
(12)
|
(15)
|
|
Operating Income |
4
N/A
|
4
+2%
|
3
-27%
|
2
-44%
|
(10)
N/A
|
(10)
-1%
|
(9)
+10%
|
(9)
+0%
|
|
Pre-Tax Income | |||||||||
Interest Income Expense |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
Non-Reccuring Items |
(4)
|
0
|
1
|
0
|
(6)
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
|
Pre-Tax Income |
0
N/A
|
4
+1 678%
|
4
-14%
|
2
-50%
|
(15)
N/A
|
(10)
+35%
|
(9)
+9%
|
(9)
+0%
|
|
Net Income | |||||||||
Tax Provision |
(1)
|
(1)
|
(1)
|
(2)
|
4
|
2
|
2
|
2
|
|
Income from Continuing Operations |
(1)
|
4
|
3
|
0
|
(11)
|
(7)
|
(7)
|
(7)
|
|
Net Income (Common) |
(1)
N/A
|
4
N/A
|
3
-29%
|
1
-56%
|
(11)
N/A
|
(7)
+35%
|
(7)
+10%
|
(7)
+1%
|
|
EPS (Diluted) |
-0.09
N/A
|
0.45
N/A
|
0.32
-29%
|
0.14
-56%
|
-1.33
N/A
|
-0.85
+36%
|
-0.77
+9%
|
-0.76
+1%
|